Physician profile
Yamen Smadi
NPI 1194930198
$593,074.79
in general payments reported to CMS, 2019-2025
15 companies · $232K in 2025
The $232K reported for 2025 was more than what 99% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.25 · 2020: $16.94 · 2021: $39.91 · 2022: $31K · 2023: $145K · 2024: $184K · 2025: $232K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $469K · Travel and Lodging: $46K · Consulting Fee: $38K · Food and Beverage: $8,042 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $469,279.50 |
| Travel and Lodging | $45,996.83 |
| Consulting Fee | $38,105.00 |
| Food and Beverage | $8,041.80 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $315,756.02 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $247,302.10 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $13,701.72 | 2024-2025 | Eohilia |
| Regeneron Pharmaceuticals, INC. | $10,515.30 | 2023-2025 | Dupixent |
| Evoendo, INC | $4,937.49 | 2023-2024 | |
| Coloplast Corp | $337.47 | 2019-2025 | Speedicath, Peristeen |
| Abbvie INC. | $162.65 | 2020-2024 | |
| Mirum Pharmaceuticals, INC. | $125.00 | 2025 | Livmarli |
| Albireo Pharma, INC. | $106.26 | 2023 | Bylvay |
| Sandoz INC. | $32.88 | 2024 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $30.34 | 2023 | Stelara |
| Alcresta Therapeutics, INC. | $26.52 | 2023 | Relizorb |
| Qol Medical, LLC | $22.81 | 2023 | Sucraid |
| Janssen Biotech, INC. | $18.23 | 2024 | Tremfya |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yamen Smadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.